Document Detail


Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
MedLine Citation:
PMID:  25406429     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Curative treatments for patients with metastatic synovial sarcoma (SS) do not exist, and such patients have a poor prognosis. We explored combinations of molecularly-targeted and cytotoxic agents to identify synergistic treatment combinations in SS cells.
METHODS: Two SS cell lines (HS-SY-II and SYO-I) were treated with single agents or combinations of molecularly targeted therapies (HDAC inhibitor, vorinostat; mTOR inhibitor, ridaforolimus) and cytotoxic agents. After 72 hours, cell viability was measured using the MTS cell proliferation assay. Combination Indices (CI) were calculated to determine whether each combination was synergistic, additive, or antagonistic. Western Blot analysis assessed alterations in total and phospho-AKT protein levels in response to drug treatment.
RESULTS: We determined the single-agent IC50 for ridaforolimus, vorinostat, doxorubicin, and melphalan in HS-SY-II and SYO-I. Synergism was apparent in cells co-treated with ridaforolimus and vorinostat: CI was 0.28 and 0.63 in HS-SY-II and SYO-I, respectively. Ridaforolimus/doxorubicin and ridaforolimus/melphalan exhibited synergism in both cell lines. An additive effect was observed with combination of vorinostat/doxorubicin in both cell lines. Vorinostat/melphalan was synergistic in HS-SY-II and additive in SYO-I. Western blot analysis demonstrated that ridaforolimus increased pAKT-ser473 levels; this effect was abrogated by vorinostat co-treatment.
CONCLUSIONS: The combination of ridaforolimus and vorinostat demonstrates in vitro synergism in SS. Addition of vorinostat abrogated ridaforolimus-induced AKT activation. Since AKT activation is a possible mechanism of resistance to mTOR inhibitors, adding vorinostat (or another HDAC inhibitor) may be a route to circumvent AKT-mediated resistance to mTOR inhibitors.
Authors:
Sherif S Morgan; Lee D Cranmer
Related Documents :
10411959 - Computer-assisted morphometry of cell-substratum contacts.
7493629 - Motility of vinculin-deficient f9 embryonic carcinoma cells analyzed by video, laser co...
15470429 - Pleiotropy as a mechanism to stabilize cooperation.
7388899 - Motility, linear arrangement and cell-to-cell contact of myogenic cells prior to fusion.
15340009 - The role of myosin heavy chain phosphorylation in dictyostelium motility, chemotaxis an...
25439029 - Increasing leucine concentration stimulates mechanistic target of rapamycin signaling a...
3250849 - Spatial organization of the epithelium and the role of neural crest cells in the initia...
18690739 - Shape effects of nanoparticles conjugated with cell-penetrating peptides (hiv tat ptd) ...
294069 - Description of the population and ultrastructure of cells on iuds.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-18
Journal Detail:
Title:  BMC research notes     Volume:  7     ISSN:  1756-0500     ISO Abbreviation:  BMC Res Notes     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-11-19     Completed Date:  -     Revised Date:  2014-11-20    
Medline Journal Info:
Nlm Unique ID:  101462768     Medline TA:  BMC Res Notes     Country:  -    
Other Details:
Languages:  ENG     Pagination:  812     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of thoracoscopic segmentectomy and thoracoscopic lobectomy on the patients with non-small...
Next Document:  Factors affecting recompression of augmented vertebrae after successful percutaneous balloon kyphopl...